The pharmacological characterization of 3,4-dihydroxyphenylimino-2-imidazolidine (DPI) as a potent mixed alpha 1/alpha 2-adrenoceptor agonist rather than as a dopamine receptor agonist.
van Oene
J C
JC
Horn
A S
AS
D000316:Adrenergic alpha-Agonists; D000818:Animals; D002395:Catecholamines / Q000494:pharmacology*; D048288:Imidazolines; D008954:Models, Biological; D051381:Rats; D011954:Receptors, Dopamine / Q000187:drug effects*
D000316:Adrenergic alpha-Agonists; D002395:Catecholamines; D048288:Imidazolines; D011954:Receptors, Dopamine; C011775:(3,4-dihydroxyphenylamino)-2-imidazoline